$GOVX
GeoVax Labs, Inc.

2024 Q4 Form 10-Q Financial Statement

#000143774924034530 Filed on November 12, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3 2023 Q3
Revenue $2.789M $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.241M $1.650M
YoY Change -24.78% 32.07%
% of Gross Profit
Research & Development $7.403M $6.948M
YoY Change 6.55% 155.33%
% of Gross Profit
Depreciation & Amortization $30.41K $20.00K
YoY Change 52.05% 13.19%
% of Gross Profit
Operating Expenses $8.644M $8.600M
YoY Change 0.52% 116.59%
Operating Profit -$5.855M -$8.600M
YoY Change -31.92% 116.59%
Interest Expense $39.11K $190.0K
YoY Change -79.42%
% of Operating Profit
Other Income/Expense, Net $39.11K $190.9K
YoY Change -79.52% 7754.22%
Pretax Income -$5.815M -$8.410M
YoY Change -30.85% 111.94%
Income Tax
% Of Pretax Income
Net Earnings -$5.815M -$8.409M
YoY Change -30.84% 111.91%
Net Earnings / Revenue -208.48%
Basic Earnings Per Share -$0.91 -$0.32
Diluted Earnings Per Share -$0.91 -$0.32
COMMON SHARES
Basic Shares Outstanding 9.436M 5.264M 26.44M
Diluted Shares Outstanding

Balance Sheet

Concept 2024 Q4 2024 Q3 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $8.593M $12.69M
YoY Change -32.29% -63.41%
Cash & Equivalents $8.593M $12.69M
Short-Term Investments
Other Short-Term Assets $1.729M $2.110M
YoY Change -18.04% 44.5%
Inventory
Prepaid Expenses
Receivables $547.6K
Other Receivables $0.00
Total Short-Term Assets $10.87M $14.80M
YoY Change -26.56% -59.04%
LONG-TERM ASSETS
Property, Plant & Equipment $171.6K $213.0K
YoY Change -19.41% -14.47%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $71.01K $1.188M
YoY Change -94.02% -45.62%
Total Long-Term Assets $242.6K $1.401M
YoY Change -82.68% -42.43%
TOTAL ASSETS
Total Short-Term Assets $10.87M $14.80M
Total Long-Term Assets $242.6K $1.401M
Total Assets $11.11M $16.20M
YoY Change -31.41% -58.0%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.148M $4.213M
YoY Change -49.02% 290.33%
Accrued Expenses $460.2K $2.868M
YoY Change -83.96% -22.68%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.608M $7.082M
YoY Change -63.17% 47.86%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.608M $7.082M
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $2.608M $7.080M
YoY Change -63.16% 4.28%
SHAREHOLDERS EQUITY
Retained Earnings -$121.1M -$96.77M
YoY Change 25.13% 32.54%
Common Stock $129.6M $105.9M
YoY Change 22.39% 1.05%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $8.504M $9.119M
YoY Change
Total Liabilities & Shareholders Equity $11.11M $16.20M
YoY Change -31.41% -58.0%

Cashflow Statement

Concept 2024 Q4 2024 Q3 2023 Q3
OPERATING ACTIVITIES
Net Income -$5.815M -$8.409M
YoY Change -30.84% 111.91%
Depreciation, Depletion And Amortization $30.41K $20.00K
YoY Change 52.05% 13.19%
Cash From Operating Activities -$9.297M -$5.100M
YoY Change 82.3% 34.24%
INVESTING ACTIVITIES
Capital Expenditures $20.65K $10.00K
YoY Change 106.5% -119.28%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$20.65K -$10.00K
YoY Change 106.5% -80.72%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 16.35M 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -9.297M -5.100M
Cash From Investing Activities -20.65K -10.00K
Cash From Financing Activities 16.35M 0.000
Net Change In Cash 7.031M -5.110M
YoY Change -237.59% -235.38%
FREE CASH FLOW
Cash From Operating Activities -$9.297M -$5.100M
Capital Expenditures $20.65K $10.00K
Free Cash Flow -$9.318M -$5.110M
YoY Change 82.35% 36.37%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Investment Income Interest
InvestmentIncomeInterest
674835 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
190936 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
70236 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-5815468 usd
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
87-0455038
dei Entity Address Address Line1
EntityAddressAddressLine1
1900 Lake Park Drive, Suite 380
dei Entity Address City Or Town
EntityAddressCityOrTown
Smyrna
dei Entity Address State Or Province
EntityAddressStateOrProvince
GA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
30080
dei City Area Code
CityAreaCode
678
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
9436069
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8592523 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6452589 usd
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
2147952 usd
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
460220 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
2608172 usd
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
8609308
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1977152
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
11112048 usd
CY2024Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
2789484 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
5763338 usd
CY2024Q1 govx Stock Issued During Period Value Warrant Exercise
StockIssuedDuringPeriodValueWarrantExercise
0 usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Transition Report
DocumentTransitionReport
false
dei Entity Registrant Name
EntityRegistrantName
GEOVAX LABS, INC.
dei Local Phone Number
LocalPhoneNumber
384-7220
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Small Business
EntitySmallBusiness
true
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
8609 usd
CY2024Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
129588694 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-121093427 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
8503876 usd
CY2023Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
0 usd
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
3090161 usd
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7402884 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6947979 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16105480 usd
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1241176 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1651775 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3784559 usd
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
8644060 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
8599754 usd
us-gaap Operating Expenses
OperatingExpenses
19890039 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-8599754 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-16799878 usd
CY2024Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
53191 usd
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
190936 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
91611 usd
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8609308
CY2024Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
37500 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-5064042 usd
dei Entity File Number
EntityFileNumber
001-39563
CY2024Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
547574 usd
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
0 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1433153 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
10869423 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
7885742 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
171615 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
209689 usd
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
71010 usd
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1187788 usd
CY2024Q3 us-gaap Assets
Assets
11112048 usd
CY2023Q4 us-gaap Assets
Assets
9283219 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4562293 usd
us-gaap Operating Expenses
OperatingExpenses
19049189 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-5854576 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-19049189 usd
CY2024Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
14083 usd
CY2023Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
-0 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
21375 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
-0 usd
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
39108 usd
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0000832489
ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1729326 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2802950 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
716931 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3519881 usd
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
600000000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1977152
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
1977 usd
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
110125146 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-104363785 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
5763338 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
9283219 usd
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
0 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14486896 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
674835 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-8408818 usd
us-gaap Net Income Loss
NetIncomeLoss
-16729642 usd
us-gaap Net Income Loss
NetIncomeLoss
-18374354 usd
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.91
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.75
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.52
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-10.42
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6404797
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1769604
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3701145
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1762856
CY2024Q1 govx Stock Issued During Period Value Reverse Stock Splits
StockIssuedDuringPeriodValueReverseStockSplits
0 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
103569 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-5850132 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
54275 usd
CY2024Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1209538 usd
CY2024Q2 govx Stock Issued During Period Value Warrant Exercise
StockIssuedDuringPeriodValueWarrantExercise
1389363 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
101640 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-2309226 usd
CY2024Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
15520877 usd
CY2024Q3 govx Stock Issued During Period Value Warrant Exercise
StockIssuedDuringPeriodValueWarrantExercise
977770 usd
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
129923 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-5815468 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
8503876 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
26600034 usd
CY2023Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
75000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
228039 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-4037916 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
22865157 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
226013 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-5927620 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
17163550 usd
CY2023Q3 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
137500 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
227114 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-8408818 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
9119346 usd
us-gaap Net Income Loss
NetIncomeLoss
-16729642 usd
us-gaap Net Income Loss
NetIncomeLoss
-18374354 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
73727 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
51956 usd
us-gaap Share Based Compensation
ShareBasedCompensation
389299 usd
us-gaap Share Based Compensation
ShareBasedCompensation
813499 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
547574 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-0 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
312840 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
707084 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-1116778 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-986498 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-911709 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
2333791 usd
us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
-192319 usd
us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
3478660 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-16921961 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14895694 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
20653 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
29997 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-20653 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-29997 usd
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
135000 usd
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
0 usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
150000 usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
-0 usd
govx Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
16730415 usd
govx Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
0 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
2367133 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
19082548 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
2139934 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-14925691 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
6452589 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
27612732 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
8592523 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
12687041 usd
us-gaap Nature Of Operations
NatureOfOperations
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody><tr style="vertical-align: top;"> <td style="width: 36pt;"> <p style="margin: 0pt; text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><b>1.</b></p> </td> <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><b>Nature of Business </b></p> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">GeoVax Labs, Inc., headquartered in the Atlanta, Georgia metropolitan area, is a clinical-stage biotechnology company incorporated under the laws of the State of Delaware. GeoVax Labs, Inc. and its wholly owned subsidiary, GeoVax, Inc., a Georgia corporation, are collectively referred to herein as “GeoVax” or “the Company”.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company is focused on developing human vaccines for many of the world’s most threatening infectious diseases and therapies for solid tumor cancers using novel proprietary platforms. GeoVax’s lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine for which it was recently awarded a BARDA-funded contract to sponsor a 10,000-participant Phase 2b clinical trial to evaluate the efficacy of GEO-CM04S1 versus an approved COVID-19 vaccine. In addition, GEO-CM04S1 is currently in three Phase 2 clinical trials, being evaluated as (1) a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, (2) a booster vaccine in patients with chronic lymphocytic leukemia (CLL) and (3) a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. The lead oncological clinical program is Gedeptin®, a novel oncolytic solid tumor gene-directed therapy, which is currently in a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. Additional preclinical research and development programs include preventive vaccines against Mpox (formerly known as monkeypox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, and Marburg), and Zika virus, as well as immunotherapies for solid tumors.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">  </p>
CY2024Q3 govx Prepaid Clinical Trial Expenses Current
PrepaidClinicalTrialExpensesCurrent
1706281 usd
CY2023Q4 govx Prepaid Clinical Trial Expenses Current
PrepaidClinicalTrialExpensesCurrent
1282746 usd
CY2024Q3 us-gaap Prepaid Insurance
PrepaidInsurance
0 usd
CY2023Q4 us-gaap Prepaid Insurance
PrepaidInsurance
110695 usd
CY2024Q3 us-gaap Prepaid Rent
PrepaidRent
13045 usd
CY2023Q4 us-gaap Prepaid Rent
PrepaidRent
13045 usd
CY2024Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
10000 usd
CY2023Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
26667 usd
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1729326 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1433153 usd
CY2024Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
911016 usd
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
890363 usd
CY2024Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
739401 usd
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
680674 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
171615 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
209689 usd
CY2024Q3 govx Prepaid Clinical Trial Expenses Noncurrent
PrepaidClinicalTrialExpensesNoncurrent
0 usd
CY2023Q4 govx Prepaid Clinical Trial Expenses Noncurrent
PrepaidClinicalTrialExpensesNoncurrent
1106778 usd
CY2024Q3 govx Prepaid Technology License Fees
PrepaidTechnologyLicenseFees
60000 usd
CY2023Q4 govx Prepaid Technology License Fees
PrepaidTechnologyLicenseFees
70000 usd
CY2024Q3 us-gaap Security Deposit
SecurityDeposit
11010 usd
CY2023Q4 us-gaap Security Deposit
SecurityDeposit
11010 usd
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
71010 usd
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1187788 usd
CY2024Q3 us-gaap Accrued Salaries Current And Noncurrent
AccruedSalariesCurrentAndNoncurrent
169719 usd
CY2023Q4 us-gaap Accrued Salaries Current And Noncurrent
AccruedSalariesCurrentAndNoncurrent
114337 usd
CY2024Q3 govx Accrued Clinical Trial Costs
AccruedClinicalTrialCosts
220501 usd
CY2023Q4 govx Accrued Clinical Trial Costs
AccruedClinicalTrialCosts
490635 usd
CY2024Q3 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
70000 usd
CY2023Q4 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
111959 usd
CY2024Q3 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
460220 usd
CY2023Q4 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
716931 usd
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
600000000
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2024Q1 us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
6703
CY2024Q1 us-gaap Stock Issued During Period Shares Reverse Stock Splits
StockIssuedDuringPeriodSharesReverseStockSplits
55422
CY2024Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
6617747
CY2024Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
655314 usd
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y10M24D
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6951395
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1026862

Files In Submission

Name View Source Status
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
0001437749-24-034530-index-headers.html Edgar Link pending
0001437749-24-034530-index.html Edgar Link pending
0001437749-24-034530.txt Edgar Link pending
0001437749-24-034530-xbrl.zip Edgar Link pending
ex_744201.htm Edgar Link pending
ex_744202.htm Edgar Link pending
ex_744203.htm Edgar Link pending
ex_744204.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
govx-20240930.xsd Edgar Link pending
govx20240930_10q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
govx-20240930_cal.xml Edgar Link unprocessable
govx-20240930_lab.xml Edgar Link unprocessable
govx-20240930_pre.xml Edgar Link unprocessable
govx20240930_10q_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable
govx-20240930_def.xml Edgar Link unprocessable